- Scientific Advisory Boards consulted for the next stages of development and regulatory approval of Estelle® and Donesta® – Mithra’s late stage contraceptive and menopause candidates
https://www.mithra.com/wp-content/uploads/2018/11/CP19-11-18.jpg 2767 4286 Mithra Pharmaceuticals https://www.mithra.com/wp-content/uploads/2017/05/logo-mithra-women-s-health.png Mithra Pharmaceuticals2018-11-19 07:30:112018-11-19 00:51:52Full Estetrol (E4) Program Update Provided at Scientific Advisory Board Meetings
Liège, Belgium, 19 November 2018 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces that it held two scientific advisory board (SAB) meetings in New Orleans (LA) at the end of October to discuss the progress in the development plans for Estelle® and Donesta®, Mithra’s key programs for contraception and menopause. The SABs, composed of American and Canadian experts in these fields, provided constructive feedback on the recently completed EU/Russia phase III trials for Estelle®. Guidance on the phase III clinical development plan for Donesta®, Mithra’s next generation hormonal therapy, was also received.
Rue Saint-Georges 5
Tel. : +32 (0)4 349 28 22
Fax : +32 (0)4 349 28 21
Email : firstname.lastname@example.org